On 1 July 2025, Pharma Japan reported that Celltrion will launch Steqeyma® (CT-P43), biosimilar to J&J/Janssen’s Stelara® (ustekinumab), in Japan on 8 July 2025.
Celltrion’s biosimilar ustekinumab launch follows Alvotech/Fuji Pharma’s launch of AVTO4 (ustekinumab) in May 2024 and Biocon/Yoshindo’s Ustekinumab BS Subcutaneous Injection, launched in May 2025.
Samsung Bioepis may be next in line, following its announcement on 9 June 2025 that it had entered into a partnership agreement with NIPRO Corporation in Japan for multiple biosimilars, including SB17, Samsung Bioepis’ ustekinumab biosimilar.
Celltrion’s Steqeyma® was launched in the US in March 2025 and in the EU in November 2024.